Find Therapeutics is focused on developing innovative therapies for autoimmune diseases, particularly through the precision-targeting of membrane receptors. Their lead compound, FTX-101, is a first-in-class therapeutic peptide designed to modulate the Plexin A1/Neuropilin 1 receptor complex in the brain, which plays a crucial role in promoting remyelination. This compound aims to address conditions such as Chronic Optic Neuropathy, a debilitating disease characterized by the loss of myelin in the optic nerve, leading to significant visual impairment. The company has initiated a Phase 1 clinical trial to assess the safety and pharmacokinetics of FTX-101, marking a significant milestone in their research and development efforts.

In addition to FTX-101, Find Therapeutics employs a Peptide Discovery Engine that enables the intelligent design of peptides targeting transmembrane domains of pharmacologically relevant receptors. This platform allows for the development of highly specific peptide therapeutics that can interfere with key protein-protein interactions involved in various biological processes. The company is also exploring other G protein-coupled receptors (GPCRs) related to autoimmune diseases of the gastrointestinal tract, aiming to discover new peptides and small molecules that could serve as potential therapies. Overall, Find Therapeutics is committed to addressing the unmet medical needs in the field of autoimmune diseases through their innovative approaches and multidisciplinary expertise.

Canada

We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases.

Dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases, our company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and an exclusive global license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard.

Find Therapeutics

Company Details